As with the early medical cannabis plays, a cluster of ASX-listed stocks has wasted little time attaching itself to the c word. Were talking of course about the coronavirus COVID-19 but sadly not another c word: cure.
Or not yet.
According to broker Morgans daily tally, the virulent bug has so far infected 95,332 people, with 38,564 current cases (6,883 of them critical).
Of the remaining 56,768 cases with an outcome, 53,483 recovered and 6,883 achieved a definitive performance indicator.They died.
Okay, a circa 7 per cent mortality rate or even a 1 or 2 per cent rate is nothing to sneeze at, so to speak. But we do wish breathless TV reporters would cease referring to it as the deadly virus, but that would be like asking them to stop referring to a horror smash rather than a sad everyday road accident.
While were on it, we also implore folk to stop hoarding toilet paper: after all, its the coronavirus, not the Caroma-virus.
Named after its crown-like shape but not the Royal Family per se, the common coronavirus is responsible for past pestilences including Severe Acute Respiratory Syndrome (SARS) and Middle Eastern Respiratory Syndrome (MERS).
The virus may indeed fizzle out, as the earlier SARS plague did.
But for the time being, we need the best and brightest minds in the labs to come up with a treatment or more likely a vaccine.
There are some promising developments overseas, which your columnist will return to if he hasnt succumbed as well (he did shake hands with someone who went to a Chinese restaurant a couple of weeks back).
Among the local biotechs and we use the term loosely theres been no lack of endeavour in linking their efforts to the virus.
But to be fair, in some cases investors did it for them.
Take Biotron (ASX:BIT), which was an obvious subject of attention given the company is focused on developing antiviral drugs for HIV and hepatitis.
Biotron also has a program for pan respiratory viruses and mentioned corona in a June 2019 presentation. Some punters latched on to the fact that it wasnt referring to a 1970s Toyota or Mexican beer and the Hot Copper pundits were off and running.
Biotron CEO Dr Michelle Miller has been more circumspect.
Yes, she says, the company has some good advanced compounds to work on, but the reality is that theres nothing that would be ready to fight the current outbreak.
Dr Miller says while the companys work on pan respiratory viruses continues, theres not much to add at this stage.
LISTEN TO: Health Kick Podcast: Coronavirus, HIV and hepatitis are in the sights of Aussie biotech Biotron
Uscom (ASX:UCM) shares went on a run after the company reported increased orders for its haemodynamic monitoring devices in China.
Uscom stands for Ultra-Sonic Cardiac Output Monitors.
The Uscom 1A device is a non-invasive diagnostic that monitors cardiovascular functions, using Doppler ultrasound to detect abnormalities.
Chinese health authorities have recommended Uscom 1A as a monitoring device for severe coronavirus cases, while international guidelines also suggest using the device for paediatric sepsis.
Uscom reported that in the first five weeks of 2019, Chinese sales orders rose 124 per cent, from 17 units to 38 units.
Uscom chief Professor Rob Phillips says the company is well positioned with the virus, but notes that Uscom is not a coronavirus story as such: fatalities from cardiovascular pulmonary failure result from conditions such as pneumonia.
Happily for Uscom, the outbreak comes as the company hones-in on the Chinese market with a new direct sales model.
READ: Dr Borehams Crucible: Uscom gets an A+ for everything but its share price
The molecular diagnostics house has a suite of approved tests that cover gastro-enteric strains, flavivirus/alphavirus, sexually-transmitted diseases and drum roll respiratory pathogens.
Genetic Signatures (ASX:GSS) Easyscreen tests cover pan coronaviruses, which until now has not been able to distinguish COVID-19 from, say, SARS.
But thats all changed, with the company introducing a supplementary test that does just that. Management is fast-tracking a validation program to obtain the data required for international regulatory approvals as rapidly as possible.
However, Genetic Signatures cant be accused of beating up its prospects: management says while the bug presents significant opportunities, the outcome of the emerging pandemic is uncertain.
While the early-stage coronavirus is detected by a blood test, chest x-rays are then used to gauge the severity of the illness and assess fluid in the lungs.
Micro-X (ASX:MX1) is all about developing lightweight and portable x-ray machines for medical applications, as well as other purposes such as defence and airports.
The companys first product, Carestream DRX Revolution Nano is approved in the US and Europe.
In mid-February the company said it had procured orders for $780,000 of machines from governments of two Asian countries, in response to the coronavirus threat. This week, another $1m of orders, all marked for urgent delivery, flooded in.
While these are terrible circumstances with the coronavirus spreading so quickly, we are pleased that our equipment will soon be able to assist medical teams with their responses in affected countries, Micro-X CEO Peter Rowland says.
Why waste a crisis? No fewer than four ASX stocks are capitalising on demand for hand and surface sanitisers to halt the bug in the first place.
Antimicrobial solutions house Zoono Group (ASX:ZNO) proclaims that its impressively-monikered Z-71 Microbe Shield, as used in its hand sanitisers, kills COVID-19 99.99 percent of the time.
Zoono is selling into China via a tie up with Eagle Health (ASX:EHH), which manufactures and distributes product into 26 provinces.
READ: Health: Zoono is not one to waste a crisis as epidemics beef up revenue
Aeris Environmental (ASX:AEI) goes one step better, claiming its Aeris Active product kills influenza and noroviruses in 99.999 percent of cases.
For those remaining 0.001 percent, bad luck and dont buy a lottery ticket.
Interestingly, that announcement did not refer specifically to the coronavirus. But earlier, Aeris announced the Singapore National Environment Agency had listed Aeris Active as one of the general disinfectants effective against the virus.
Meanwhile, fruit juice maker Food Revolution Group (ASX:FOD) has turned from filling its bottles with squeezed oranges to stuffing them with alcohol-based hand sanitiser under the Sanicare brand.
Who would have thought? The swift repositioning results from a 1,260sqm upgrade at the companys plant at Mill Park in outer Melbourne, which enables all sorts of gels, powders, oils and cosmetics to be bottled.
Mainstream sanitiser products such as Dettol and Lysol (made by multinational Reckitt and Benckiser) are flying off the shelves.
But is a good scrub with soap and water just as effective? Australian National University microbiologist Professor Peter Collignon opines theres little difference between hand washing and the alcohol-based sanitisers.
One is just more convenient than the other and contains alcohol, he says. You can put it in your pocket and dont have to be near a sink or basin to use it.
So whos actually tackling the disease? Offshore, theres a conga line of developers having a crack at a vaccine.
In Israel, scientists at the Galilee Research Institute claim to be on the cusp of finalising a product that is capable of getting regulatory assent within 90 days.
Thats what you call fast-track approval.
According to the Jerusalem Post, the same team of scientists has been developing a prophylactic against infectious bronchitis virus, which affects poultry.
The effectiveness of the vaccine has been proven in pre-clinical trials carried out at the countrys Veterinary Institute.
In the US, Gilead Sciences plans to recruit 1,000 patients with coronavirus for a clinical trial to test its experimental anti-viral drug remdesivir (as used to tackle Ebola virus).
With the backing of the World Health Organisation, the drug is also being trialed in China.
Maryland-based, Nasdaq-listed Novavax says it is cloning the coronavirus to develop a vaccine, in the same way it developed one for MERS in 2013.
Novavax is looking at several vaccine candidates for animals and hopes to find one for human testing by the end of May.
Our previous experience working with other coronaviruses, including both MERS and SARS, allowed us to mobilise quickly, Novavax CEO Stanley Eck said.
Fellow Nasdaq minnow Moderna has shipped an experimental vaccine to the National Institute of Allergy and Infectious Diseases for testing.
Backed by billionaire hedge fund founder Jim Simons, Long Island-based private outfit Codagenixexpects to have a vaccine ready for animal testing in four to six weeks, with one suitable for testing about six weeks later.
The Codagenix know-how is based on recoding the genomes of viruses to render them harmless. The technique is not exactly unknown, as its been used to eradicate polio and small pox.
And who can forget Australias very own Relenza anti-influenza Biota, which became Alpharetta Georgias Nabi, changed its name to Aviragen and then was subsumed as a sub-division of San Franciscos Vaxart, popping its head above the parapet to also claim an anti-viral program for COVID-19.
READ: Biotech big guns are buying up the minnows
The South China Morning Post reports that a 65-year-old woman on her COVID-19 deathbed walked out of Chinas Kunming Hospital after being given a stiff shot of mesenchymal stem cells (MSCs).
Two trials are also underway to test the therapy against pneumonia, at a Beijing Military Hospital and Zhongnan Hospital of Wuhan University (yep, in the coronavirus capital).
Could the excitement rub-off on our ASX-listed plays Mesoblast (ASX:MSB), Cynata Therapeutics (ASX:CYP), Orthocell (ASX:OCC) and Regeneus (ASX:RGS)?
Cynatas Dr Ross Macdonald says the reports look authentic; and he believes that MSCs could be an effective adjunct in managing patients with serious issues pertaining to COVID-19.
This is not because MSCs are inherently anti-viral or can act as a vaccine, but more because they have shown benefit in major pathologies associated with infection, he says.
Cynata, we stress, has not mentioned coronavirus in its dispatches and nor has any of the other non-China MSC plays or not yet anyway.
But still, what decent CEO would not give his company a plug?
The clear advantage of (Cynatas) Cymerus technology (is) the ability to make large quantities of consistent, robust MSCs without having to find gazillions of donors, Dr Macdonald says.
Your columnist stresses that the coronavirus influence on the sector is not all positive, with some biotechs likely to be affected by supply or other disruptions.
In mid-February, Cochlear (ASX:COH) quickly stepped off the mark by announcing its earnings for the 2019-20 year were likely to come in at $270-290m, compared with the previously guided $290-300m.
The reason is that hospitals in China and Hong Kong have delayed cochlear implant procedures to avoid the risk of infection.
The aforementioned Uscom notes that with labs preoccupied with the virus, short-term revenues are less predictable. In other words, the coronavirus is a distraction as well as an opportunity.
IDT Australias (ASX:IDT)Dr David Sparling told Biotech Daily that his company had no direct supply chain exposure to China at all, and was doubtful that even the companys gowns and protective gear had much to do with the Middle Kingdom.
If you throw enough money and resources at tackling a disease you will get a result, right?
Er, not quite: cures for well-researched ailments such as Alzheimers disease, multiple sclerosis and an array of cancers remain elusive.
But when youve got an ailment that is crippling the global economy, the imperative to find a solution is somewhat more intensive.
Our best guess is that like SARS and MERS, COVID-19 will hang around for years to come, but the ill-effects will be made more tolerable with an effective vaccine and/or improved immunity over time.
In other words, it will become just another disease in the pantheon of maladies blighting humanity.
In the race for a cure, Gileads Remdesivir looks interesting, given it has been used before.
As for the opportunists in the sanitiser game, the surge in demand means tangible revenue gains and good on them.
But lets be clear: theyre hardly breaking new ground technology-wise and their gains will only be short term as other suppliers enter the market.
As for a cure, or lack of one, we suggest that investors hedge their bets with an exposure to the funeral stocks Invocare (ASX:IVC)and Propel Funeral Partners (ASX:PFP).
After all, theyre the last people to let you down.
Disclosure: Dr Boreham is not a qualified medical practitioner and does not possess a doctorate of any sort. If he doesnt shake hands with you or spare you a square of toilet paper, dont be offended.
This column first appeared in Biotech Daily.
NOW LISTEN TO:
Get the latest Stock & Small Caps news and insights direct to your inbox.
See the original post:
Dr Borehams Crucible: The small cap biotechs trying to make a buck from coronavirus - Stockhead
- Pluristyx, panCELLa, and Implant Therapeutics Announce Definitive Merger Agreement - Business Wire - October 13th, 2022
- Johns Hopkins Scientists Have Developed a Nanobody That May Treat Parkinson's Disease - SciTechDaily - September 25th, 2022
- UMD students contribute to tech, health fields with summer research projects - The Diamondback - September 16th, 2022
- Pair of Hopkins teams receive $200K in technology grants - Maryland Daily Record - August 22nd, 2022
- RoosterBio and AGC Biologics team up to accelerate manufacture of cell and exosome therapies - BioPharma-Reporter.com - August 22nd, 2022
- Stem Cell Transplant Reverses Sickle Cell Disease in Adults - July 3rd, 2022
- LONGEVERON INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com - May 15th, 2022
- Top Ways To Rejuvenate Your Body And Improve Your Well-being - The Southern Maryland Chronicle - April 19th, 2022
- BioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering from Acute Respiratory Distress... - April 19th, 2022
- Synthetic biology's past, present and future explored in timely new account - Winnipeg Free Press - April 6th, 2022
- US is Out of Step on Primate Research With Rest of World - NewsClick - October 5th, 2021
- A Look Inside A Termite's Gut Wins The 11th Annual Nikon Small World in Motion Competition - PRNewswire - August 18th, 2021
- What really happened in Wuhan? - The Sunday Guardian Live - The Sunday Guardian - June 6th, 2021
- UMD Researchers Perform Crucial Proof-of-Concept ... - December 20th, 2020
- US gets more help in raging battle against COVID-19 as FDA authorizes Moderna vaccine, the second allowed for emergency use - USA TODAY - December 20th, 2020
- Sirnaomics to Initiate Phase I Study of STP705 in Treatment of Primary and Metastatic Liver Cancer | DNA RNA and Cells | News Channels -... - December 7th, 2020
- Trump was one of the first 10 patients to get an experimental COVID-19 treatment under special use - Yahoo News - October 8th, 2020
- New toilet, a VR camera and science experiments are heading to t - KAKE - October 8th, 2020
- ShoreRivers awarded DNR grant for two restoration projects - MyEasternShoreMD - August 26th, 2020
- CRISPR cows could boost sustainable meat production, but regulations and wary consumers stand in the way - Genetic Literacy Project - August 26th, 2020
- Over $8M in 2020 Stem Cell Funding Awards Continue to Fuel Marylands Leading Cell Therapy Industry - BioBuzz - June 24th, 2020
- Researchers develop nanoengineered bioink to 3D print functional bone tissue - 3D Printing Industry - May 27th, 2020
- 'Virus Goes In, Virus Goes Out': Advocates Call For Release Of More Low-Level Prisoners To Stem Infection Rate - Kaiser Health News - May 22nd, 2020
- What Do New Neurons in the Brains of Adults Actually Do? - The Scientist - May 7th, 2020
- David C. Karli is Offering a New Ray of Hope Through Regenerative Medicine - RESPECT. - May 3rd, 2020
- Could Innate Immunology Save Us From the Coronavirus? - The New York Times - May 3rd, 2020
- Watch: Hogan orders closure of bars, restaurants, theaters and gyms, restricts gatherings - Maryland Daily Record - March 22nd, 2020
- The Aussie Biotech Companies Trying To Make A Buck From Coronavirus - D'Marge - March 9th, 2020
- Organoids, iPSCs, and advanced cell models: Advancing discovery from basic research to drug discovery - Science Magazine - March 4th, 2020
- Maryland Stem Cell Center Consortium & Core Facility ... - March 4th, 2020
- Serving those who serve - The Hub at Johns Hopkins - November 14th, 2019
- BioLineRx Presents Preclinical Data From Triple Combination of BL-8040, Anti PD-1 and Chemotherapy Demonstrating Significant Reduction in Pancreatic... - November 6th, 2019
- VetStem Biopharma Shares the Success Story of Ole who was Treated with VetStem Cell Therapy by Dr. Holly Mullen - PR Web - November 6th, 2019
- Contrasting of Applied Therapeutics Inc. (APLT) and Neuralstem Inc. (NASDAQ:CUR) - MS Wkly - November 6th, 2019
- Reviewing Synthetic Biologics Inc. (SYN)'s and Asterias Biotherapeutics Inc. (:)'s results - FinanceMercury - November 6th, 2019
- Comparing of Neuralstem Inc. (CUR) and Allakos Inc. (NASDAQ:ALLK) - MS Wkly - November 6th, 2019
- Head-To-Head Survey: Intrexon (NASDAQ:XON) versus US Stem Cell (NASDAQ:USRM) - Riverton Roll - September 25th, 2019
- Analyzing US Stem Cell (OTCMKTS:USRM) and Intrexon (OTCMKTS:XON) - TechNewsObserver - September 25th, 2019
- Reviewing Intrexon (NASDAQ:XON) & US Stem Cell (NASDAQ:USRM) - Mayfield Recorder - September 25th, 2019
- Artificially Engineering Intestine - Mirage News - September 25th, 2019
- Prothena Corporation plc (PRTA)'s Financial Results Comparing With Neuralstem Inc. (NASDAQ:CUR) - The EN Herald - September 25th, 2019
- cord_blood - Maryland - September 14th, 2019
- Stem Cells and Type 1 Diabetes: What the Future Has in ... - April 24th, 2019
- Stem Cell Therapy in Maryland | Stem Cell Professionals - April 5th, 2019
- Meristem - Wikipedia - January 17th, 2019
- Stem Cell Therapy in Annapolis Maryland | Stem Cell ... - October 25th, 2018
- Stem Cell Centers - Towson > Stem Cell Centers - October 6th, 2018
- STEM CELL THERAPY - Orthopedic and Wellness Maryland - September 5th, 2018
- Patient Resources | University of Maryland School of Medicine - September 5th, 2018
- Stem Cell Clinical Trial | University of Maryland Children ... - August 17th, 2018
- Baltimore, Maryland Stem Cell Transplants, Montgomery ... - August 17th, 2018
- Nervous System Stem Cells Can Replace Themselves, Give ... - July 3rd, 2018
- Excellence in Stem Cell Research | University of Maryland ... - June 24th, 2018
- Maryland Stem Cell Research Fund: 2014 Awardees - June 24th, 2018
- Catholic response to stem cells - Featured Today ... - October 14th, 2017
- Free stem cell Essays and Papers - 123HelpMe - October 12th, 2017
- How Stem Cell Therapy Can Help Repair and Regenerate Your Body - October 12th, 2017
- How Stem Cell Therapy Can Help Repair and ... - Mercola.com - September 4th, 2017
- Science and technology to get boost from CRS-12 mission - SpaceFlight Insider - August 12th, 2017
- Cannon Scholars visit National Institute of Standards and Technology - Dover Post - August 9th, 2017
- Lab-Grown, Virus-Free Stem Cells Repair Retinal Tissue in ... - August 9th, 2017
- Roanoke researchers pursue treatments for the type of deadly brain cancer affecting McCain - Roanoke Times - August 3rd, 2017
- The Maryland Stem Cell Research Fund (MSCRF) | Tedco - November 25th, 2016
- Center for Stem Cell Biology & Regenerative Medicine ... - November 14th, 2016
- Ginger | University of Maryland Medical Center - September 6th, 2016
- Johns Hopkins Team Creates Stem Cells From Schizophrenia ... - September 5th, 2016
- Human Induced Pluripotent Stem Cell Derived Neuronal Cells ... - August 18th, 2016
- Maryland Stem Cell Center Consortium and Core Facility ... - August 12th, 2016
- Human Stem Cells Institute - Wikipedia, the free encyclopedia - October 19th, 2015
- Patients' Own Genetically Altered Immune Cells Show ... - October 19th, 2015
- Maryland Stem Cell Research Fund: Funding Opportunities - July 2nd, 2015
- MRI based on a sugar molecule can tell cancerous from noncancerous cells - March 27th, 2015
- MD Stem Cells Release Optic Nerve Vision Loss Reversed ... - March 22nd, 2015
- TiGenix: TiGenix reports its full year 2014 results - March 18th, 2015
- Gene regulatory path revealed as target for therapy of aggressive pediatric brain cancer - March 10th, 2015
- American Spine offers experimental fix for pain -- Gazette.Net - January 28th, 2015
- American Spine offers experimental fix for pain - January 28th, 2015
- Toughest Breast Cancer May Have Met Its Match - December 9th, 2014
- Bid on Stem Cells and Alcohol-induced Tissue Injuries (R21 ... - November 12th, 2014
- Head, National Institutes of Health Stem Cell Technology ... - November 11th, 2014